Compare Agilysys Inc (AGYS) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance

Agilysys (AGYS) trades at $106.14, down 0.79% for the day, with a bullish technical signal from moving averages and a consensus analyst price target of $118.33. Recent Q1 2026 earnings beat expectations with EPS of $0.63 versus $0.4971, and the company raised its full-year outlook, driven by strong subscription revenue growth and deployment progress with key clients like Marriott.

The outlook is positive given robust earnings momentum and 100% buy ratings from analysts, though high valuation multiples (P/E of 70.01) and negative net cash flow in 2025 pose risks. Upside potential exists if subscription-led growth continues, but investors should monitor execution against elevated expectations.

Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.

While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.